Literature DB >> 29663302

Multivisceral Resection for Locally Advanced Gastric and Gastroesophageal Junction Cancers-11-Year Experience at a High-Volume North American Center.

J C Molina1, A Al-Hinai2, A Gosseling-Tardif2, P Bouchard2, J Spicer2, D Mulder2, C L Mueller2, L E Ferri2.   

Abstract

INTRODUCTION: The oncologic benefit of multivisceral en bloc resections for T4 gastroesophageal tumors has been questioned, given the increased morbidity associated. We thus sought to investigate the surgical and oncologic outcomes of curative-intent en bloc multivisceral resections for T4 gastroesophageal carcinomas.
METHODS: Between 2005 and 2016, 35 of the 525 patients who had gastric or EGJ carcinomas underwent curative-intent multivisceral resections for direct invasion or adhesion to adjacent organs.
RESULTS: Postoperative complications occurred in 16(46%), 10 of which were Clavien-Dindo ≥ 3 (29%). Ninety-day mortality was 3%. The R0 resection rate was 94% (33). Direct organ invasion (pT4b) was confirmed on pathological analysis in 14 (40%) and did not affect survival. The majority (28, 80%) had lymph node involvement with a high nodal disease burden and was associated with decreased survival. Overall 5-year survival rate was 34%, and the vast majority of recurrences were distant/peritoneal (81%). On multivariate analysis, positive lymph nodes (H.R. 21.2; 95%CI 2.34-192) and R1 resection (H.R. 5.6; 95%CI 1.02-30.9) were predictors of survival.
CONCLUSION: Multivisceral resections for T4 gastric and GEJ adenocarcinomas, in combination with effective systemic therapy, result in prolonged long-term survival with acceptable morbidity. Complete resection to negative margins should remain a mainstay of curative-intent treatment in carefully selected patients.

Entities:  

Keywords:  Gastric cancer; Locally advanced; Surgery; T4

Mesh:

Year:  2018        PMID: 29663302     DOI: 10.1007/s11605-018-3746-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  38 in total

1.  Is there a benefit of pancreaticosplenectomy with gastrectomy for advanced gastric cancer?

Authors:  Y Kasakura; M Fujii; F Mochizuki; M Kochi; T Kaiga
Journal:  Am J Surg       Date:  2000-03       Impact factor: 2.565

2.  Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.

Authors:  Monisha Sudarshan; Thierry Alcindor; Steven Ades; Abdullah Aloraini; Marie van Huyse; Jamil Asselah; Marc David; Dominique Frechette; Sonia Brisson; Michael Thirlwell; Lorenzo Ferri
Journal:  Ann Surg Oncol       Date:  2014-07-15       Impact factor: 5.344

3.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  E C Smyth; M Verheij; W Allum; D Cunningham; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

4.  Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012 edited by the Japan Esophageal Society.

Authors:  Hiroyuki Kuwano; Yasumasa Nishimura; Tsuneo Oyama; Hiroyuki Kato; Yuko Kitagawa; Motoyasu Kusano; Hideo Shimada; Hiroya Takiuchi; Yasushi Toh; Yuichiro Doki; Yoshio Naomoto; Hisahiro Matsubara; Tatsuya Miyazaki; Manabu Muto; Akio Yanagisawa
Journal:  Esophagus       Date:  2014-11-11       Impact factor: 4.230

5.  Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial.

Authors:  L E Ferri; S Ades; T Alcindor; M Chasen; V Marcus; M Hickeson; G Artho; M P Thirlwell
Journal:  Ann Oncol       Date:  2011-10-29       Impact factor: 32.976

6.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group.

Authors:  A Cuschieri; P Fayers; J Fielding; J Craven; J Bancewicz; V Joypaul; P Cook
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

Review 7.  Prognostic factors in gastric cancer.

Authors:  H Allgayer; M M Heiss; F W Schildberg
Journal:  Br J Surg       Date:  1997-12       Impact factor: 6.939

Review 8.  Multivisceral resection for gastric cancer: a systematic review.

Authors:  Savtaj S Brar; Rajini Seevaratnam; Roberta Cardoso; Lavanya Yohanathan; Calvin Law; Lucy Helyer; Natalie G Coburn
Journal:  Gastric Cancer       Date:  2011-07-23       Impact factor: 7.370

9.  Appropriate selection of patients for combined organ resection in cases of gastric carcinoma invading adjacent organs.

Authors:  Oh Jeong; Won Yong Choi; Young Kyu Park
Journal:  J Surg Oncol       Date:  2009-08-01       Impact factor: 3.454

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  3 in total

1.  Multivisceral Resection for Locally Advanced Gastric Cancer.

Authors:  John G Aversa; Laurence P Diggs; Brendan L Hagerty; Dana A Dominguez; Philip H G Ituarte; Jonathan M Hernandez; Jeremy L Davis; Andrew M Blakely
Journal:  J Gastrointest Surg       Date:  2020-07-23       Impact factor: 3.267

2.  Risk Factors and Prognostic Impact of Postoperative Complications in Patients with Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy.

Authors:  Hong Yu; Li Xu; Songcheng Yin; Jianlong Jiang; Chunhong Hong; Yulong He; Changhua Zhang
Journal:  Curr Oncol       Date:  2022-09-10       Impact factor: 3.109

3.  Short-term safety and Long-term efficacy of multivisceral resection in pT4b gastric cancer patients without distant metastasis: a 20-year experience in China National Cancer Center.

Authors:  Xiaojie Zhang; Wanqing Wang; Lulu Zhao; Penghui Niu; Chunguang Guo; Dongbing Zhao; Yingtai Chen
Journal:  J Cancer       Date:  2022-08-15       Impact factor: 4.478

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.